Key result
Subcutaneous ICD therapy demonstrates promising performance and efficacy in patients beyond classical indications, including those with Brugada syndrome or hypertrophic cardiomyopathy.
Why the study?
S-ICD therapy indications are broadening beyond classical candidates without coverage by randomized controlled trials, creating a need for an updated review of empirical evidence and technical advancements in expanded indications.
Design
Review
Authors
Loading...
May support S-ICD consideration in Brugada syndrome and HCM; leaves open need for prospective trials.
This review highlights the expanding indications and promising performance of S-ICD therapy beyond classical candidates, including in complex conditions like Brugada syndrome and hypertrophic cardiomyopathy.
Bögeholz et al. (2019) conducted a review in Patients requiring ICD therapy without demand for pacing. Subcutaneous ICD (S-ICD) therapy was evaluated. Subcutaneous ICD therapy demonstrates promising performance and efficacy in patients beyond classical indications, including those with Brugada syndrome or hypertrophic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: